Table 3 Lassa virus vaccine candidate platforms in preclinical development
From: Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development
LASV candidate | Test species | Antigen/virus strain | No. of doses | Dose | Time to challenge | Survival | Test parameter | Date | Ref. |
|---|---|---|---|---|---|---|---|---|---|
Recombinant vesicular stomatitis virus (rVSV) | Guinea pig strain 13 | GPC/Strain Josiah | 1 | 106 PFU | 28 d | 100% | Antibody | 2015 | |
|  | Cynomolgus monkey | GPC/Strain Josiah | 1 | 2-6 × 107 PFU | 28 d | 100% | Antibody and T cell IFN-γ | 2015 2005 | |
DNA | Guinea pig strain 13 | GPC/Strain Josiah | 3 | 100 µg | 63 d | 100% | Antibody | 2013 | |
Venezuelan equine encephalitis (VEE)-like replicon | Mouse CBA/J | GPC/Strain Josiah | 2 | Unknown | Unknown | 100% | T cell IFN- γ | 2012 | |
|  | Guinea pig strain 13 | NP or GPC/Strain Josiah | 3 | 107 IU | 84 d | 100% | Antibody | 2001 | |
Recombinant yellow fever 17D | Guinea pig strain 13 | GPC/Strain AV | 1 | 105 PFU | 21 d | 80% | Antibody | 2006 | |
|  | Guinea pig strain 13 | GP1 & GP2/Strain Josiah | 2 | 5 × 106 PFU | 44 d | 83% | Antibody | 2011 | |
| Â | Marmoset | GPC/Strain Josiah | 2 | Unknown | 30 d | 0% | Unknown | 2012 | |
Recombinant mopeia/Lassa virus (ML29) | Guinea pig strain 13 | GPC & NP/Strain Josiah | 1 | 103 PFU | 30 d | 100% (60–100% protection with simultaneous replication of ML29 and LASV Strain Josiah) | Antibody | 2007 2005 | |
|  | Marmoset | GPC & NP/Strain Josiah | 1 | 103 PFU | 30 d | 100% | Antibody and T cell IFN-γ | 2008 | |
Salmonella vectored LASV-NP | BALB/c mice | NP/ Strain unknown | 2 | 5 × 109 CFU | 25 d | 37% | Antibody and CTL activity | 2001, 2000 | |
Mopeia virus | Rhesus monkey | Whole Virus Strain/ Unknown | 1 | 104 PFU | 37 d | 100% | Antibody | 1998 | |
Vaccinia (Lister) vectored virus | Guinea pig Hartley | NP/Strain GA391 | 1 | 107 PFU | 28 d | 100% | Unknown | 1987 | |
Vaccinia (NYBH) vectored virus | Rhesus monkey | GPC/Unknown | 1 | 109 PFU | 28-37 d | 100% | Antibody | 1998 | |
| Â | Rhesus and cynomolgus monkeys | GP1, GP2, GPC, NP, GPC/NP/ Strain Josiah | 1 or 2 | 109 PFU | 62-488 d | 89% GPC 90% GPC/NP | Antibody | 2000 | |
Inactivated virus | Rhesus monkey | Whole Virus Strain/ Unknown | 6 | Unknown | 108 d | 0% | Antibody | 1992 | |
Nanocarrier with recombinant GP1 (envelope glycoprotein) encapsulated into polymersomes | C57BL/6 mice | GP1/Unknown | 2 | 10 μg | 14 and 28 d | 0% (all animals sacrificed at 28 d; no survival data) | Antibody/CD4 T cell/B cell | 2017 | |
Modified vaccinia Ankara-virus like particle (MVA-VLP) | Mouse species not declared | Not declared | 1 | 103 PFU | 10 d | 100% | T cell | 2017 |
